Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2016

Published: Sep, 2016 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2016', provides an overview of the Lee's Pharmaceutical Holdings Limited's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Lee's Pharmaceutical Holdings Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Lee's Pharmaceutical Holdings Limited
- The report provides overview of Lee's Pharmaceutical Holdings Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Lee's Pharmaceutical Holdings Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Lee's Pharmaceutical Holdings Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Lee's Pharmaceutical Holdings Limited's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Lee's Pharmaceutical Holdings Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lee's Pharmaceutical Holdings Limited's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Lee's Pharmaceutical Holdings Limited Snapshot 7
Lee's Pharmaceutical Holdings Limited Overview 7
Key Facts 7
Lee's Pharmaceutical Holdings Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Lee's Pharmaceutical Holdings Limited - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Lee's Pharmaceutical Holdings Limited - Pipeline Products Glance 16
Lee's Pharmaceutical Holdings Limited - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Lee's Pharmaceutical Holdings Limited - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Lee's Pharmaceutical Holdings Limited - Early Stage Pipeline Products 20
IND/CTA Filed Products/Combination Treatment Modalities 20
Preclinical Products/Combination Treatment Modalities 21
Lee's Pharmaceutical Holdings Limited - Drug Profiles 22
(adapalene + clindamycin hydrochloride) - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
AK-12 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
azilsartan - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
gimatecan - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
istaroxime - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
levobetaxolol hydrochloride - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
levocarnitine propionate hydrochloride - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LQ-7 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
pazufloxacin - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
procarbazine hydrochloride - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
RGN-259 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
rostafuroxin - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
STIA-1014 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
tecarfarin sodium - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
trazodone hydrochloride - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ZK-001 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ZK-002 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ZK-003 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ZK-004 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ZK-009 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ZK-010 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ZK-011 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ZK-012 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ZK-013 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
ZK-014 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ZK-015 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ZK-016 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Lee's Pharmaceutical Holdings Limited - Pipeline Analysis 61
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Target 61
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 63
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Molecule Type 64
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action 65
Lee's Pharmaceutical Holdings Limited - Dormant Projects 67
Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products 68
Discontinued Pipeline Product Profiles 68
betrixaban 68
ecallantide 68
gimatecan 68
NOV-002 69
NOV-205 69
prulifloxacin 69
RGN-259 69
Lee's Pharmaceutical Holdings Limited - Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70

Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables

Lee's Pharmaceutical Holdings Limited, Key Facts 7
Lee's Pharmaceutical Holdings Limited - Pipeline by Indication, 2016 9
Lee's Pharmaceutical Holdings Limited - Pipeline by Stage of Development, 2016 11
Lee's Pharmaceutical Holdings Limited - Monotherapy Products in Pipeline, 2016 12
Lee's Pharmaceutical Holdings Limited - Combination Treatment Modalities in Pipeline, 2016 13
Lee's Pharmaceutical Holdings Limited - Partnered Products in Pipeline, 2016 14
Lee's Pharmaceutical Holdings Limited - Partnered Products/ Combination Treatment Modalities, 2016 15
Lee's Pharmaceutical Holdings Limited - Pre-Registration, 2016 16
Lee's Pharmaceutical Holdings Limited - Phase III, 2016 17
Lee's Pharmaceutical Holdings Limited - Phase II, 2016 18
Lee's Pharmaceutical Holdings Limited - Phase I, 2016 19
Lee's Pharmaceutical Holdings Limited - IND/CTA Filed, 2016 20
Lee's Pharmaceutical Holdings Limited - Preclinical, 2016 21
Lee's Pharmaceutical Holdings Limited - Pipeline by Target, 2016 62
Lee's Pharmaceutical Holdings Limited - Pipeline by Route of Administration, 2016 63
Lee's Pharmaceutical Holdings Limited - Pipeline by Molecule Type, 2016 64
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action, 2016 66
Lee's Pharmaceutical Holdings Limited - Dormant Developmental Projects,2016 67
Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products, 2016 68
Lee's Pharmaceutical Holdings Limited, Subsidiaries 70